한글목차

HIV 치료제 시장 - 조사 범위

TMR의 조사 보고서 "세계 HIV 치료제 시장"은 2024-2034년 예측 기간 동안 시장 지표에 대한 귀중한 인사이트를 얻기 위해 과거뿐만 아니라 현재의 성장 동향과 기회를 조사하고 있습니다. 이 보고서는 2024년을 기준 연도, 2034년을 예측 연도로 하여 2018-2034년까지의 세계 HIV 치료제 시장의 수익과 예측을 제공합니다. 또한 2024년부터 2034년까지 세계 HIV 치료제 시장의 복합 연간 성장률(CAGR %)을 제시합니다.

이 보고서는 광범위한 조사를 통해 작성되었으며, 1차 조사에서 분석가들은 주요 오피니언 리더, 업계 리더 및 오피니언 메이커를 대상으로 인터뷰를 진행했습니다. 2차 조사에서는 주요 기업의 제품 자료, 연례 보고서, 보도자료, 관련 자료 등을 참고하여 HIV 치료제 시장을 추론했습니다.

이 보고서는 세계 HIV 치료제 시장의 경쟁 환경을 조사하고 있습니다. 세계 HIV 치료제 시장에서 사업을 전개하는 주요 업체들이 확인되었으며, 각 업체들은 다양한 속성으로 프로파일링되어 있습니다. 회사 개요, 재무 상태, 최근 동향, SWOT 등이 이 보고서에서 소개되는 세계 HIV 치료제 시장 진입 기업의 속성입니다.

목차

제1장 서문

제2장 가정과 조사 방법

제3장 주요 요약 : 세계 시장

제4장 시장 개요

• 소개
• 개요
• 시장 역학
• 세계의 시장 분석과 예측, 2020-2034년

제5장 주요 인사이트

• 파이프라인 분석
• 주요 제품/브랜드 분석
• 주요 M&A
• COVID-19의 산업에 대한 영향

제6장 세계의 시장 분석과 예측 : 약물 유형별

• 소개와 정의
• 주요 조사 결과·발전
• 시장 금액 예측 : 약물 유형별, 2020-2034년
  • 뉴클레오시드 역전사효소 억제제(NRTI)
  • 비뉴클레오시드계 역전사효소 억제제(NNRTI)
  • 프로테아제 억제제(PI)
  • 융합 억제제(FI)
  • C-C 케모카인 수용체 5형(CCR5)
  • 인테그라제 억제제
  • 부착 억제제
  • 부착 후 억제제
  • 약제 동태 증강제
  • 노출 후 예방(PEP)
  • 노출 전 예방(PrEP)
  • 기타(HIV 치료제 병용 등)
• 시장 매력 분석 : 약물 유형별

제7장 세계의 시장 분석과 예측 : 유통 채널별

• 소개와 정의
• 주요 조사 결과·발전
• 시장 금액 예측 : 유통 채널별, 2020-2034년
  • 병원 약국
  • 소매 약국
  • 온라인 약국
• 시장 매력 분석 : 유통 채널별

제8장 세계의 시장 분석과 예측 : 지역별

• 주요 조사 결과
• 시장 금액 예측 : 지역별, 2020-2034년
  • 북미
  • 유럽
  • 아시아태평양
  • 라틴아메리카
  • 중동 및 아프리카
• 시장 매력 분석 : 지역별

제9장 북미의 시장 분석과 예측

제10장 유럽의 시장 분석과 예측

제11장 아시아태평양의 시장 분석과 예측

제12장 라틴아메리카 시장 분석과 예측

제13장 중동 및 아프리카의 시장 분석과 예측

제14장 경쟁 상황

• 시장 기업 - 경쟁 매트릭스(기업 계층과 규모별)
• 시장 점유율 분석 : 기업별(2023년)
• 기업 개요
  • Teva Pharmaceutical Industries Ltd.
  • Boehringer Ingelheim International GmbH
  • Johnson & Johnson
  • F. Hoffmann-La Roche Ltd.
  • Gilead Sciences, Inc.
  • GSK plc
  • AbbVie Inc.
  • Cipla Limited
  • Bristol-Myers Squibb Company
  • Merck & Co., Inc.

영문목차

HIV Drugs Market - Scope of Report

TMR's report on the global HIV drugs market studies the past as well as the current growth trends and opportunities to gain valuable insights of the indicators of the market during the forecast period from 2024 to 2034. The report provides revenue of the global HIV drugs market for the period 2018-2034, considering 2024 as the base year and 2034 as the forecast year. The report also provides the compound annual growth rate (CAGR %) of the global HIV drugs market from 2024 to 2034.

The report has been prepared after an extensive research. Primary research involved bulk of the research efforts, wherein analysts carried out interviews with key opinion leaders, industry leaders, and opinion makers. Secondary research involved referring to key players' product literature, annual reports, press releases, and relevant documents to understand the HIV drugs market.

Secondary research also included Internet sources, statistical data from government agencies, websites, and trade associations. Analysts employed a combination of top-down and bottom-up approaches to study various attributes of the global HIV drugs market.

The report includes an elaborate executive summary, along with a snapshot of the growth behavior of various segments included in the scope of the study. Moreover, the report throws light on the changing competitive dynamics in the global HIV drugs market. These serve as valuable tools for existing market players as well as for entities interested in participating in the global HIV drugs market.

The report delves into the competitive landscape of the global HIV drugs market. Key players operating in the global HIV drugs market have been identified and each one of these has been profiled in terms of various attributes. Company overview, financial standings, recent developments, and SWOT are the attributes of players in the global HIV drugs market profiled in this report.

Key Questions Answered in Global HIV drugs Market Report:

• What is the sales/revenue generated by HIV drugs across all regions during the forecast period?
• What are the opportunities in the global HIV drugs market?
• What are the major drivers, restraints, opportunities, and threats in the market?
• Which regional market is set to expand at the fastest CAGR during the forecast period?
• Which segment is expected to generate the highest revenue globally in 2034?
• Which segment is projected to expand at the highest CAGR during the forecast period?
• What are the market positions of different companies operating in the global market?

HIV Drugs Market - Research Objectives and Research Approach

The comprehensive report on the global HIV drugs market begins with an overview, followed by the scope and objectives of the study. The report provides detailed explanation of the objectives behind this study and key vendors and distributors operating in the market and regulatory scenario for approval of products.

For reading comprehensibility, the report has been compiled in a chapter-wise layout, with each section divided into smaller ones. The report comprises an exhaustive collection of graphs and tables that are appropriately interspersed. Pictorial representation of actual and projected values of key segments is visually appealing to readers. This also allows comparison of the market shares of key segments in the past and at the end of the forecast period.

The report analyzes the global HIV drugs market in terms of product, end-user, and region. Key segments under each criterion have been studied at length, and the market share for each of these at the end of 2034 has been provided. Such valuable insights enable market stakeholders in making informed business decisions for investment in the global HIV drugs market.

Table of Contents

1. Preface

• 1.1. Market Definition and Scope
• 1.2. Market Segmentation
• 1.3. Key Research Objectives
• 1.4. Research Highlights

2. Assumptions and Research Methodology

3. Executive Summary: Global HIV Drugs Market

4. Market Overview

• 4.1. Introduction
  • 4.1.1. Product Definition
  • 4.1.2. Industry Evolution/Developments
• 4.2. Overview
• 4.3. Market Dynamics
  • 4.3.1. Drivers
  • 4.3.2. Restraints
  • 4.3.3. Opportunities
• 4.4. Global HIV Drugs Market Analysis and Forecast, 2020-2034

5. Key Insights

• 5.1. Pipeline Analysis
• 5.2. Key Product/Brand Analysis
• 5.3. Key Mergers & Acquisitions
• 5.4. COVID-19 Pandemic Impact on Industry

6. Global HIV Drugs Market Analysis and Forecast, by Drug Type

• 6.1. Introduction & Definition
• 6.2. Key Findings/Developments
• 6.3. Market Value Forecast, by Drug Type, 2020-2034
  • 6.3.1. Nucleoside Reverse Transcriptase Inhibitors (NRTIs)
  • 6.3.2. Non-Nucleoside Reverse Transcriptase Inhibitors (NNRTIs)
  • 6.3.3. Protease Inhibitors (PIs)
  • 6.3.4. Fusion Inhibitors (FIs)
  • 6.3.5. C-C Chemokine Receptor Type 5 (CCR5)
  • 6.3.6. Integrase Inhibitors
  • 6.3.7. Attachment Inhibitors
  • 6.3.8. Post Attachment Inhibitors
  • 6.3.9. Pharmacokinetic Enhancers
  • 6.3.10. Post-Exposure Prophylaxis (PEP)
  • 6.3.11. Pre-Exposure Prophylaxis (PrEP)
  • 6.3.12. Others (Combination HIV Medications, etc.)
• 6.4. Market Attractiveness Analysis, by Drug Type

7. Global HIV Drugs Market Analysis and Forecast, by Distribution Channel

• 7.1. Introduction & Definition
• 7.2. Key Findings/Developments
• 7.3. Market Value Forecast, by Distribution Channel, 2020-2034
  • 7.3.1. Hospital Pharmacies
  • 7.3.2. Retail Pharmacies
  • 7.3.3. Online Pharmacies
• 7.4. Market Attractiveness Analysis, by Distribution Channel

8. Global HIV Drugs Market Analysis and Forecast, by Region

• 8.1. Key Findings
• 8.2. Market Value Forecast, by Region, 2020-2034
  • 8.2.1. North America
  • 8.2.2. Europe
  • 8.2.3. Asia Pacific
  • 8.2.4. Latin America
  • 8.2.5. Middle East & Africa
• 8.3. Market Attractiveness Analysis, by Region

9. North America HIV Drugs Market Analysis and Forecast

• 9.1. Introduction
• 9.2. Key Findings
• 9.3. Market Value Forecast, by Drug Type, 2020-2034
  • 9.3.1. Nucleoside Reverse Transcriptase Inhibitors (NRTIs)
  • 9.3.2. Non-Nucleoside Reverse Transcriptase Inhibitors (NNRTIs)
  • 9.3.3. Protease Inhibitors (PIs)
  • 9.3.4. Fusion Inhibitors (FIs)
  • 9.3.5. C-C Chemokine Receptor Type 5 (CCR5)
  • 9.3.6. Integrase Inhibitors
  • 9.3.7. Attachment Inhibitors
  • 9.3.8. Post Attachment Inhibitors
  • 9.3.9. Pharmacokinetic Enhancers
  • 9.3.10. Post-Exposure Prophylaxis (PEP)
  • 9.3.11. Pre-Exposure Prophylaxis (PrEP)
  • 9.3.12. Others (Combination HIV Medications, etc.)
• 9.4. Market Value Forecast, by Distribution Channel, 2020-2034
  • 9.4.1. Hospital Pharmacies
  • 9.4.2. Retail Pharmacies
  • 9.4.3. Online Pharmacies
• 9.5. Market Value Forecast, by Country, 2020-2034
  • 9.5.1. U.S.
  • 9.5.2. Canada
• 9.6. Market Attractiveness Analysis
  • 9.6.1. By Drug Type
  • 9.6.2. By Distribution Channel
  • 9.6.3. By Country

10. Europe HIV Drugs Market Analysis and Forecast

• 10.1. Introduction
• 10.2. Key Findings
• 10.3. Market Value Forecast, by Drug Type, 2020-2034
  • 10.3.1. Nucleoside Reverse Transcriptase Inhibitors (NRTIs)
  • 10.3.2. Non-Nucleoside Reverse Transcriptase Inhibitors (NNRTIs)
  • 10.3.3. Protease Inhibitors (PIs)
  • 10.3.4. Fusion Inhibitors (FIs)
  • 10.3.5. C-C Chemokine Receptor Type 5 (CCR5)
  • 10.3.6. Integrase Inhibitors
  • 10.3.7. Attachment Inhibitors
  • 10.3.8. Post Attachment Inhibitors
  • 10.3.9. Pharmacokinetic Enhancers
  • 10.3.10. Post-Exposure Prophylaxis (PEP)
  • 10.3.11. Pre-Exposure Prophylaxis (PrEP)
  • 10.3.12. Others (Combination HIV Medications, etc.)
• 10.4. Market Value Forecast, by Distribution Channel, 2020-2034
  • 10.4.1. Hospital Pharmacies
  • 10.4.2. Retail Pharmacies
  • 10.4.3. Online Pharmacies
• 10.5. Market Value Forecast, by Country/Sub-region, 2020-2034
  • 10.5.1. Germany
  • 10.5.2. U.K.
  • 10.5.3. France
  • 10.5.4. Italy
  • 10.5.5. Spain
  • 10.5.6. Rest of Europe
• 10.6. Market Attractiveness Analysis
  • 10.6.1. By Drug Type
  • 10.6.2. By Distribution Channel
  • 10.6.3. By Country/Sub-region

11. Asia Pacific HIV Drugs Market Analysis and Forecast

• 11.1. Introduction
• 11.2. Key Findings
• 11.3. Market Value Forecast, by Drug Type, 2020-2034
  • 11.3.1. Nucleoside Reverse Transcriptase Inhibitors (NRTIs)
  • 11.3.2. Non-Nucleoside Reverse Transcriptase Inhibitors (NNRTIs)
  • 11.3.3. Protease Inhibitors (PIs)
  • 11.3.4. Fusion Inhibitors (FIs)
  • 11.3.5. C-C Chemokine Receptor Type 5 (CCR5)
  • 11.3.6. Integrase Inhibitors
  • 11.3.7. Attachment Inhibitors
  • 11.3.8. Post Attachment Inhibitors
  • 11.3.9. Pharmacokinetic Enhancers
  • 11.3.10. Post-Exposure Prophylaxis (PEP)
  • 11.3.11. Pre-Exposure Prophylaxis (PrEP)
  • 11.3.12. Others (Combination HIV Medications, etc.)
• 11.4. Market Value Forecast, by Distribution Channel, 2020-2034
  • 11.4.1. Hospital Pharmacies
  • 11.4.2. Retail Pharmacies
  • 11.4.3. Online Pharmacies
• 11.5. Market Value Forecast, by Country/Sub-region, 2020-2034
  • 11.5.1. China
  • 11.5.2. Japan
  • 11.5.3. India
  • 11.5.4. Australia & New Zealand
  • 11.5.5. Rest of Asia Pacific
• 11.6. Market Attractiveness Analysis
  • 11.6.1. By Drug Type
  • 11.6.2. By Distribution Channel
  • 11.6.3. By Country/Sub-region

12. Latin America HIV Drugs Market Analysis and Forecast

• 12.1. Introduction
• 12.2. Key Findings
• 12.3. Market Value Forecast, by Drug Type, 2020-2034
  • 12.3.1. Nucleoside Reverse Transcriptase Inhibitors (NRTIs)
  • 12.3.2. Non-Nucleoside Reverse Transcriptase Inhibitors (NNRTIs)
  • 12.3.3. Protease Inhibitors (PIs)
  • 12.3.4. Fusion Inhibitors (FIs)
  • 12.3.5. C-C Chemokine Receptor Type 5 (CCR5)
  • 12.3.6. Integrase Inhibitors
  • 12.3.7. Attachment Inhibitors
  • 12.3.8. Post Attachment Inhibitors
  • 12.3.9. Pharmacokinetic Enhancers
  • 12.3.10. Post-Exposure Prophylaxis (PEP)
  • 12.3.11. Pre-Exposure Prophylaxis (PrEP)
  • 12.3.12. Others (Combination HIV Medications, etc.)
• 12.4. Market Value Forecast, by Distribution Channel, 2020-2034
  • 12.4.1. Hospital Pharmacies
  • 12.4.2. Retail Pharmacies
  • 12.4.3. Online Pharmacies
• 12.5. Market Value Forecast, by Country/Sub-region, 2020-2034
  • 12.5.1. Brazil
  • 12.5.2. Mexico
  • 12.5.3. Rest of Latin America
• 12.6. Market Attractiveness Analysis
  • 12.6.1. By Drug Type
  • 12.6.2. By Distribution Channel
  • 12.6.3. By Country/Sub-region

13. Middle East & Africa HIV Drugs Market Analysis and Forecast

• 13.1. Introduction
• 13.2. Key Findings
• 13.3. Market Value Forecast, by Drug Type, 2020-2034
  • 13.3.1. Nucleoside Reverse Transcriptase Inhibitors (NRTIs)
  • 13.3.2. Non-Nucleoside Reverse Transcriptase Inhibitors (NNRTIs)
  • 13.3.3. Protease Inhibitors (PIs)
  • 13.3.4. Fusion Inhibitors (FIs)
  • 13.3.5. C-C Chemokine Receptor Type 5 (CCR5)
  • 13.3.6. Integrase Inhibitors
  • 13.3.7. Attachment Inhibitors
  • 13.3.8. Post Attachment Inhibitors
  • 13.3.9. Pharmacokinetic Enhancers
  • 13.3.10. Post-Exposure Prophylaxis (PEP)
  • 13.3.11. Pre-Exposure Prophylaxis (PrEP)
  • 13.3.12. Others (Combination HIV Medications, etc.)
• 13.4. Market Value Forecast, by Distribution Channel, 2020-2034
  • 13.4.1. Hospital Pharmacies
  • 13.4.2. Retail Pharmacies
  • 13.4.3. Online Pharmacies
• 13.5. Market Value Forecast, by Country/Sub-region, 2020-2034
  • 13.5.1. GCC Countries
  • 13.5.2. South Africa
  • 13.5.3. Rest of Middle East & Africa
• 13.6. Market Attractiveness Analysis
  • 13.6.1. By Drug Type
  • 13.6.2. By Distribution Channel
  • 13.6.3. By Country/Sub-region

14. Competition Landscape

• 14.1. Market Player - Competitive Matrix (by Tier and Size of Companies)
• 14.2. Market Share Analysis, by Company (2023)
• 14.3. Company Profiles
  • 14.3.1. Teva Pharmaceutical Industries Ltd.
    • 14.3.1.1. Company Overview
    • 14.3.1.2. Product Portfolio
    • 14.3.1.3. SWOT Analysis
    • 14.3.1.4. Financial Overview
    • 14.3.1.5. Strategic Overview
  • 14.3.2. Boehringer Ingelheim International GmbH
    • 14.3.2.1. Company Overview
    • 14.3.2.2. Product Portfolio
    • 14.3.2.3. SWOT Analysis
    • 14.3.2.4. Financial Overview
    • 14.3.2.5. Strategic Overview
  • 14.3.3. Johnson & Johnson
    • 14.3.3.1. Company Overview
    • 14.3.3.2. Product Portfolio
    • 14.3.3.3. SWOT Analysis
    • 14.3.3.4. Financial Overview
    • 14.3.3.5. Strategic Overview
  • 14.3.4. F. Hoffmann-La Roche Ltd.
    • 14.3.4.1. Company Overview
    • 14.3.4.2. Product Portfolio
    • 14.3.4.3. SWOT Analysis
    • 14.3.4.4. Financial Overview
    • 14.3.4.5. Strategic Overview
  • 14.3.5. Gilead Sciences, Inc.
    • 14.3.5.1. Company Overview
    • 14.3.5.2. Product Portfolio
    • 14.3.5.3. SWOT Analysis
    • 14.3.5.4. Financial Overview
    • 14.3.5.5. Strategic Overview
  • 14.3.6. GSK plc
    • 14.3.6.1. Company Overview
    • 14.3.6.2. Product Portfolio
    • 14.3.6.3. SWOT Analysis
    • 14.3.6.4. Financial Overview
    • 14.3.6.5. Strategic Overview
  • 14.3.7. AbbVie Inc.
    • 14.3.7.1. Company Overview
    • 14.3.7.2. Product Portfolio
    • 14.3.7.3. SWOT Analysis
    • 14.3.7.4. Financial Overview
    • 14.3.7.5. Strategic Overview
  • 14.3.8. Cipla Limited
    • 14.3.8.1. Company Overview
    • 14.3.8.2. Product Portfolio
    • 14.3.8.3. SWOT Analysis
    • 14.3.8.4. Financial Overview
    • 14.3.8.5. Strategic Overview
  • 14.3.9. Bristol-Myers Squibb Company
    • 14.3.9.1. Company Overview
    • 14.3.9.2. Product Portfolio
    • 14.3.9.3. SWOT Analysis
    • 14.3.9.4. Financial Overview
    • 14.3.9.5. Strategic Overview
  • 14.3.10. Merck & Co., Inc.
    • 14.3.10.1. Company Overview
    • 14.3.10.2. Product Portfolio
    • 14.3.10.3. SWOT Analysis
    • 14.3.10.4. Financial Overview
    • 14.3.10.5. Strategic Overview